The CCL2–CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells
Anticancer Research · 2023
DOI: 10.21873/anticanres.16423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Ariunbold Natsagdorj und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
- General Surgery, Grand Med Hospital, Ulaanbaatar, Mongolia.
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan; azuizu2003@yahoo.co.jp.
- Department of Clinical Engineering, Faculty of Health Sciences, Komatsu University, Komatsu, Japan.
Zitieren
APA
Natsagdorj, A., Izumi, K., Hiratsuka, K., Naito, R., Kadomoto, S., Iwamoto, H., Yaegashi, H., Shigehara, K., Nakata, H., & Mizokami, A. (2023). The CCL2–CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells. Anticancer Research. https://doi.org/10.21873/anticanres.16423
Vancouver
Natsagdorj A, Izumi K, Hiratsuka K, Naito R, Kadomoto S, Iwamoto H, et al. The CCL2–CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells. Anticancer Research. 2023. doi:10.21873/anticanres.16423
BibTeX
@article{Natsagdorj2023,
author = {Natsagdorj, Ariunbold and Izumi, Kouji and Hiratsuka, Kaoru and Naito, Renato and Kadomoto, Suguru and Iwamoto, Hiroaki and Yaegashi, Hiroshi and Shigehara, Kazuyoshi and Nakata, Hiroki and Mizokami, Atsushi},
title = {The CCL2–CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16423}
}
EUVIMED